Facebook
Instagram
Linkedin
Youtube
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Search
BioStock
Start
News
Studio
Events
Newsletter
About BioStock
Contact us
Career
Home
Search
curasight
-
search results
If you're not happy with the results, please do another search
Full phase II results of uPAR-PET in glioblastoma published
8 November, 2024
Curasight well-placed in hot radiopharma sector
22 October, 2024
Curasight carries out the first step of capitalization
10 September, 2024
Curasight targets clinical proof-of-concept for uTREAT
29 August, 2024
Curasight CEO comments on capital raise and milestone
25 June, 2024
Curasight committed to progressing pipeline
4 June, 2024
Curasight gets green light from EMA in phase II prostate cancer...
22 April, 2024
Curasight cancels rights issue and evaluates alternative financing
13 March, 2024
Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise
19 February, 2024
Curasight gets first milestone payment from Curium
2 February, 2024
Oncoinvent’s CEO: “Radiopharmaceuticals has emerged as the hottest space in oncology”
31 January, 2024
Curasight gears up for phase II study in prostate cancer
22 December, 2023
Curasight CEO: “Working on accelerated plan for uTREAT”
28 November, 2023
Positive preclinical results for Curasight in lung cancer
20 October, 2023
Curasight presents brain cancer results at World Molecular Imaging Congress
22 September, 2023
Curasight hope to build upon strong momentum
30 August, 2023
New positive results for Curasight in brain cancer
30 June, 2023
Positive uTREAT-results in glioblastoma for Curasight
8 June, 2023
Curasight solidifies position with Curium deal and strong financials
26 May, 2023
Curasight secures global licence agreement for uTRACE in prostate cancer
11 May, 2023
Curasight on the agreement with Curium
10 May, 2023
Curasight can look back on an eventful year
1 March, 2023
Curasight eagerly awaiting phase II-results in brain cancer
1 December, 2022
Curasight takes the next step in the two new indications
24 October, 2022
Strong momentum for Curasight in first half of 2022
2 September, 2022
Curasight ready to move forward in brain cancer
5 July, 2022
Curasight starts 2022 off strong
3 June, 2022
Curasight targets neuroendocrine tumours
27 April, 2022
Curasight expands its clinical portfolio
8 March, 2022
Positive phase II results for Curasight in neuroendocrine cancer
17 February, 2022
BioStock takes a closer look at Curasight´s potential in brain cancer
1 February, 2022
Curasight targets prostate cancer with theranostic approach
7 January, 2022
Positive phase II results for Curasight in head and neck cancer
14 December, 2021
Curasight plans further strategic advancement
29 November, 2021
Join us for the BioStock Life Science Summit on October 20...
20 October, 2021
Curasight advances in the fight against cancer
27 September, 2021
Innovation in focus at BioStock Life Science Spring Summit 2021
25 May, 2021